Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol

被引:55
|
作者
Alsheikh-Ali, Alawi A.
Lin, Jen-Liang
Abourjaily, Paul
Ahearn, Dineli
Kuvin, Jeffrey T.
Karas, Richard H. [1 ]
机构
[1] Tufts Univ New England Med Ctr, Div Cardiol & Mol Cardiol, Res Inst, Boston, MA 02111 USA
[2] Tufts Univ New England Med Ctr, Div Gen Internal Med, Dept Med, Boston, MA USA
[3] Tufts Univ, Sch Med, Boston, MA 02111 USA
来源
AMERICAN JOURNAL OF CARDIOLOGY | 2007年 / 100卷 / 10期
关键词
D O I
10.1016/j.amjcard.2007.06.058
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current guidelines identify low-density lipoprotein (LDL) cholesterol as the primary target for cardiovascular prevention but also recognize low high-density lipoprotein (HDL) cholesterol as an important secondary target. This study was conducted to determine the prevalence of low HDL cholesterol in a contemporary ambulatory high-risk population across various LDL cholesterol levels, including patients taking statins. Screening of 44,052 electronic medical records from a primary care practice identified 1,512 high-risk patients with documented coronary heart disease (CHD) or CHD risk equivalents. Low HDL cholesterol (<= 40 mg/dl in men, <= 50 mg/dl in women) was present in 66% of the 1,512 patients. Low HDL cholesterol was prevalent across all LDL cholesterol levels but most prevalent in patients with LDL cholesterol <= 70 mg/dl (79% vs 66% in those with LDL cholesterol 71 to 100 mg/dl and 64% in patients with LDL cholesterol > 100 mg/dl, p < 0.01). Low HDL cholesterol was equally and highly prevalent in patients taking statins (67%) and those not taking statins (64%) (p = NS). HDL cholesterol and LDL cholesterol levels correlated poorly (R-2 = 0.01), and this was unaffected by gender or statin treatment. In conclusion, in high-risk patients with CHD or CHD risk equivalents, low HDL cholesterol levels remain prevalent despite statin treatment and the achievement of aggressive LDL cholesterol goals. (c) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:1499 / 1501
页数:3
相关论文
共 50 条
  • [31] Value Of High-Density Lipoprotein Cholesterol In Predicting Future Cardiovascular Events Of Patients With Low-Density Lipoprotein Cholesterol At The Time Of Percutaneous Coronary Intervention
    Sardi, Gabriel
    Torguson, Rebecca
    Kitabata, Hironori
    Loh, Joshua
    Badr, Salem
    Suddath, William
    Satler, Lowell
    Kent, Kenneth
    Pichard, Augusto
    Brewer, Bryan
    Waksman, Ron
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (17) : B188 - B188
  • [32] Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities
    Rosenson, RS
    CURRENT OPINION IN CARDIOLOGY, 2005, 20 (04) : 313 - 317
  • [33] What is the target for low-density lipoprotein cholesterol in patients with heart disease?
    Stevermer, JJ
    Meadows, SE
    JOURNAL OF FAMILY PRACTICE, 2002, 51 (10): : 893 - 893
  • [34] HIGH-DENSITY AND LOW-DENSITY LIPOPROTEIN CHOLESTEROL - CORRELATES IN AN OLDER POPULATION
    BAKER, LL
    CRIQUI, MH
    PREVENTIVE MEDICINE, 1985, 14 (02) : 155 - 164
  • [35] Predictive Value of Low-Density Lipoprotein Cholesterol to High-Density Lipoprotein Cholesterol Ratio for the Prevention of Stroke Recurrence
    Igase, Michiya
    Kohara, Katsuhiko
    Miki, Tetsuro
    NEUROLOGY, 2011, 76 (09) : A630 - A630
  • [36] Blood Rheology and the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio in Dyslipidaemic and Normolipidaemic Subjects
    Machida, T.
    Sumino, H.
    Fukushima, M.
    Kotajima, N.
    Amagai, H.
    Murakami, M.
    JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2010, 38 (06) : 1975 - 1984
  • [37] Association of the Low-density Lipoprotein Cholesterol/High-density Lipoprotein Cholesterol Ratio with Glecaprevir-pibrentasvir Treatment
    Akutsu, Noriyuki
    Sasaki, Shigeru
    Matsui, Takeshi
    Akashi, Hirofumi
    Yonezawa, Kazuhiko
    Ishigami, Keisuke
    Tsujisaki, Masayuki
    Isshiki, Hiroyuki
    Yawata, Atsushi
    Yamaoka, Satoshi
    Ban, Toshihiro
    Adachi, Takeya
    Nakahara, Seiya
    Takagi, Hideyasu
    Nakachi, Kohei
    Tanaka, Katsunori
    Hirano, Takehiro
    Yamamoto, Itaru
    Kaneto, Hiroyuki
    Wagatsuma, Kohei
    Numata, Yasunao
    Nakase, Hiroshi
    INTERNAL MEDICINE, 2021, 60 (21) : 3369 - 3376
  • [38] Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol
    Adami, S
    Braga, V
    Guidi, G
    Gatti, D
    Gerardi, D
    Fracassi, E
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 (03) : 599 - 604
  • [39] Low-Density Lipoprotein Cholesterol Trajectories and Prevalence of High Low-Density Lipoprotein Cholesterol Consistent With Heterozygous Familial Hypercholesterolemia in US Children
    Zhang, Yiyi
    Woo, Jessica G.
    Urbina, Elaine M.
    Jacobs, David R., Jr.
    Moran, Andrew E.
    de Ferranti, Sarah D.
    JAMA PEDIATRICS, 2021, 175 (10) : 1071 - 1074
  • [40] Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease
    Mudd, James O.
    Boilaug, Barry A.
    Johnston, Peter V.
    Kral, Brian G.
    Rouf, Rosanne
    Blumenthal, Roger S.
    Kwiterovich, Peter O., Jr.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (18) : 1735 - 1741